Antihypertensive therapy among newly treated patients: An analysis of adherence and cost of treatment over years

ClinicoEconomics and Outcomes Research

Volumn 2, Issue 1, 2010, Pages 113-120

  Esposti, Luca Degli ^a   Saragoni, Stefania ^a   Batacchi, Paolo ^b   Geppetti, Pierangelo ^c   Buda, Stefano ^a   Esposti, Ezio Degli ^d  

^a Economics and Outcomes Research   (Italy)

^b Local Health Unit of Florence   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d Health Outcome Research Unit   (Italy)

Author keywords

Adherence; Administrative databases; Antihypertensive therapy; Cost

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREND STUDY;

EID: 77955448367     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Degli Esposti L, Valpiani G. Pharmacoeconomic burden of undertreating hypertension. Pharmacoeconomics. 2004;22(14):907-928.
2. Robbiano L, Martelli A, Brambilla G. Discrepancies between use of antihypertensive drugs and guidelines indications: Pharmacoeconomic implications. J Hum Hypertens. 2005;19(10):819-822.
3. The use of pharmaceuticals in Italy. National Report 2007. Rome: Il Pensiero Scientifico Editore; 2008.
4. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta analysis. JAMA. 2003;289(19):2534-2544.
5. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events: Second cycle of prospectively designed overviews. Lancet. 2003(9395);362:1527-1535.
6. Chalmers J. Comparison of various blood pressure lowering treatments on the primary prevention of cardiovascular outcomes in recent randomised clinical trials. Clin Exp Hypertens. 2004;26(7-8):709-719.
7. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: Meta-analysis of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. BMJ. 2008;336 (7653):1121-1223.
8. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177-186.
9. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836-1841.
10. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166(17):1842-1847.
11. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-530.
12. Kettani FZ, Dragomir A, Coté R, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke. 2009;40(1):213-220.
13. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120(16):1598-1605.
14. Degli Esposti L, Degli Esposti E, Valpiani G, et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther. 2002;24(8):1347-1357.
15. Degli Esposti L, Di Martino M, Saragoni S, et al. Pharmacoeconomics of antihypertensive drug treatment: An analysis of how long patients remain on various antihypertensive therapies. J Clin Hypertens. 2004;6(2):76-84.
16. Degli Esposti E, Sturani A, Di Martino M, et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens. 2002;16(6):439-444.
17. Caro JJ, Salas M, Speakman JL, et al. Persistence with treatment for hypertension in actual practice. Can Med Assoc J. 1999:160(1):3-7.
18. Mazzaglia G, Mantovani L, Sturkenboom MC, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: A retrospective cohort study in primary care. J Hypertens. 2005;23(11):2093-2100.
19. Corrao G, Zambon A, Parodi A, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: A population-based study in Italy. J Hypertens. 2008;26(4):819-24.
20. Breekveldt-Postma N, Penning-van Beest F, Siiskonen S, et al. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin. 2008;24(1): 121-127.
21. Catalan VS, LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health. 2000;3(6):417-426.
22. Perreault S, Dragomir A, White M, Lalonde L, Blais L, Bérard A. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med. 2009;266(2):207-218.
23. Degli Esposti L, Di Martino M, Saragoni S, Capone A, Russo P, Degli Esposti E. Cost offset of lipid-lowering drugs for primary and secondary prevention of cardiovascular disease. Expert Rev Pharmacoecon Outcomes Res. 2005;5(2):193-205.
24. Baio G, Esposti LD, Esposti ED, et al. Bayesian cost-effectiveness analysis based on the persistence with antihypertensive treatment. Expert Rev Pharmacoecon Outcomes Res. 2003;3(3):227-236.
25. Kotseva K, Wood D, De Backer D, et al; for the EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: Comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373(9667):929-940.
26. Gaziano TA, Bitton A, Anand S, et al. The global cost of non optimal blood pressure. J Hypertens. 2009;27:1472-7.
27. World Health Organization. Adherence to long-term therapies. Evidence for action. Geneva: World Health Organization; 2003.
28. Motheral BR, Fairman KA. The use of claims databases for antihypertensive drugs and associated hospitalization. Clin Ther. 1997; 19(2):346-366.
29. Birnbaum HG, Cremieux PY, Greenberg PE, et al. Using health care expenditures for healthcare claims data for outcome research and pharmaco-economic analyses. Pharmacoeconomics. 1999;16:1-8.